Previous 10 | Next 10 |
Liquid biopsies provide hope for quicker and more accurate early-stage cancer detection across a wider range of cancer types with a simple blood test. Using current standard of care, only about 25% of cancers are detected via screening. The remaining 75% are detected when the patient ...
Barcelona-based testing service will advance cancer research and enable clinicians to personalize treatments more accurately and quickly for patients with late-stage cancer Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and the Vall d’Hebron...
Oral presentation in Clinical Science Symposium will demonstrate use of real-world data from GuardantINFORM to identify resistance to early treatment in advanced breast cancer Oral presentation in Breast Cancer-Metastatic Session will highlight updated progression-free survi...
Blood-based multimodal test achieved 100% sensitivity for colorectal cancer at 90% specificity in a prospective study of 557 individuals Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced data showing its blood-based multimodal test ach...
Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. In the quarter ended March 31, 2022, Baron Health Care Fund (the “Fund”) declined 9.93% (Institutional Shar...
Aristotle Capital Management is an independent/employee-owned investment management organization that specializes in equity and fixed income portfolio management for institutional and advisory clients worldwide. For the first quarter of 2022, Aristotle Atlantic’s Large Cap Grow...
Aristotle Capital Management is an independent/employee-owned investment management organization that specializes in equity and fixed income portfolio management for institutional and advisory clients worldwide. For the first quarter of 2022, Aristotle Atlantic’s Focus Growth C...
Shares of Guardant Health (NASDAQ: GH) were trading 23.4% lower as of 11:51 a.m. ET on Friday. The steep decline came after the company announced its first-quarter results following the market close on Thursday. The medical testing specialist reported Q1 revenue of $96.1 million...
Guardant Health (NASDAQ:GH) shares have reached a 52-week low on Friday even after the maker of liquid biopsy-based cancer tests reported better than expected earnings for the first time in seven quarters with its 1Q 2022 financials. Revenue for the period rose ~22% YoY to $96.1M, driven...
Gainers: ChemoCentryx (CCXI) +19%. iRhythm Technologies (IRTC) +16%. Jounce Therapeutics (JNCE) +15%. Grifols (GRFS) +9%. Sensus Healthcare (SRTS) +8%. Losers: Joint (JYNT) -46%. Endo International (ENDP) -34%. Guardant Health (GH) -26%. Gain ...
News, Short Squeeze, Breakout and More Instantly...
Shield is first blood test approved by FDA as a primary screening option for colorectal cancer and that meets performance requirements for Medicare coverage Blood test offers easy, convenient and pleasant screening option with potential for improving colorectal cancer screening rates ...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2024 after market close on Wednesday, August 7, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Ti...
Running on Guardant Infinity™ smart liquid biopsy platform, new Guardant360 test covers over 10 times more genes, including all guideline-recommended genomic biomarkers across advanced solid tumors, and quantifies tumor burden with 10 times higher sensitivity Upgraded test covered ...